Brought to you by 
Roche licenses Plexxikon's Phase I kidney disease candidate
22 Nov 2022
Executive Summary
Continuing a relationship that began two years ago, a new agreement has Roche licensing exclusive worldwide development and commercialization rights to Plexxikon Inc.'s (small-molecule therapeutics) Phase I Raf kinase inhibitor PLX5568 for polycystic kidney disease (PKD), an inherited condition characterized by the formation of renal cysts, which if enlarged, infected, or ruptured, could result in potential kidney failure. There is currently no marketed treatment for PKD.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche licenses Plexxikon's Phase I kidney disease candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice